title: IL-2/neuroantigen fusion proteins as antigen-specific tolerogens in experimental autoimmune encephalomyelitis (EAE): correlation of T cell-mediated antigen presentation and tolerance induction.
abstract: The purpose of this study was to assess whether the Ag-targeting activity of cytokine/neuroantigen (NAg) fusion proteins may be associated with mechanisms of tolerance induction. To assess this question, we expressed fusion proteins comprised of a N-terminal cytokine domain and a C-terminal NAg domain. The cytokine domain comprised either rat IL-2 or IL-4, and the NAg domain comprised the dominant encephalitogenic determinant of the guinea pig myelin basic protein. Subcutaneous administration of IL2NAg (IL-2/NAg fusion protein) into Lewis rats either before or after an encephalitogenic challenge resulted in an attenuated course of experimental autoimmune encephalomyelitis. In contrast, parallel treatment of rats with IL4NAg (IL-4/NAg fusion protein) or NAg lacked tolerogenic activity. In the presence of IL-2R(+) MHC class II(+) T cells, IL2NAg fusion proteins were at least 1,000 times more potent as an Ag than NAg alone. The tolerogenic activity of IL2NAg in vivo and the enhanced potency in vitro were both dependent upon covalent linkage of IL-2 and NAg. IL4NAg also exhibited enhanced antigenic potency. IL4NAg was approximately 100-fold more active than NAg alone in the presence of splenic APC. The enhanced potency of IL4NAg also required covalent linkage of cytokine and NAg and was blocked by soluble IL-4 or by a mAb specific for IL-4. Other control cytokine/NAg fusion proteins did not exhibit a similar enhancement of Ag potency compared with NAg alone. Thus, the IL2NAg and IL4NAg fusion proteins targeted NAg for enhanced presentation by particular subsets of APC. The activities of IL2NAg revealed a potential relationship between NAg targeting to activated T cells, T cell-mediated Ag presentation, and tolerance induction.
authors.affiliation: Department of Microbiology and Immunology, East Carolina University School of Medicine, Greenville, NC 27834, USA. manniem@ecu.edu
authors.forename: Mark D
authors.initials: MD
authors.lastname: Mannie
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Clayson
authors.forename: Elizabeth J
authors.initials: EJ
authors.lastname: Buskirk
authors.forename: Jarret L
authors.initials: JL
authors.lastname: DeVine
authors.forename: Jose J
authors.initials: JJ
authors.lastname: Hernandez
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Abbott
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects / Q000276:immunology*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology*; D006168:Guinea Pigs; D007108:Immune Tolerance / Q000187:drug effects; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D015847:Interleukin-4 / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D004676:Myelin Basic Protein / Q000235:genetics / Q000276:immunology* / Q000494:pharmacology; D009930:Organic Chemicals / Q000276:immunology / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology
chemical_list: D007376:Interleukin-2; D004676:Myelin Basic Protein; D009930:Organic Chemicals; D011993:Recombinant Fusion Proteins; C029248:Tolerogen; D015847:Interleukin-4